Adam Gault
Baird downgraded Medpace (NASDAQ:MEDP) to neutral, citing slowed near-term revenue growth.
Baird said that while 2025 may see low single digit to mid-single digit revenue growth, if bookings recover in the second half of 2025, “then 2026 could easily return to double-digit
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。